Mutual of America Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Mutual of America Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,772	Closed	-$14K	–	1721
2020 Q1	$14K	Buy	3,772 +691	+22%	+$2.98K	﹤0.01%	1561
2019 Q4	$16K	Sell	3,081 -110	-3%	-$582	﹤0.01%	1605
2019 Q3	$16K	Buy	3,191 +160	+5%	+$798	﹤0.01%	1600
2019 Q2	$19K	Buy	3,031 +581	+24%	+$2.8K	﹤0.01%	1572
2019 Q1	$11K	Buy	2,450 +320	+15%	+$1.45K	﹤0.01%	1632
2018 Q4	$9K	Buy	2,130 +535	+34%	+$2.72K	﹤0.01%	1636
2018 Q3	$10K	Buy	1,595 +1,324	+489%	+$10.2K	﹤0.01%	1629
2018 Q2	$2K	Buy	+271	New	+$2.07K	﹤0.01%	1651

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Mutual of America Capital Management's PGNX Position: Q2 2020 in Review

Mutual of America Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 3,772 shares — an estimated $14K sold.

Mutual of America Capital Management first reported a position in PGNX in Q2 2018 and held it in 8 quarters. The position peaked at $19K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Mutual of America Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Mutual of America Capital Management sold 3,772 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $14K.
Mutual of America Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2018 and held it in 8 quarters.
Mutual of America Capital Management's Progenics Pharmaceuticals Inc position peaked at $19K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Mutual of America Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.